← Back to Search

Hypertonic Saline for Cystic Fibrosis

Phase 1
Waitlist Available
Led By Tim Corcoran, Ph.D.
Research Sponsored by Tim Corcoran
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 80 minutes
Awards & highlights

Study Summary

This trial is testing whether computer models can be used to develop new medications for lung diseases like Cystic Fibrosis (CF) by just doing lab studies on cell samples from patients' noses.

Eligible Conditions
  • Cystic Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~80 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 80 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
DTPA absorption rate
Mucociliary Clearance

Trial Design

4Treatment groups
Experimental Treatment
Group I: non CF controlsExperimental Treatment3 Interventions
Ages 18 and older with no history of lung disease Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml).
Group II: Parents of CF subjectsExperimental Treatment3 Interventions
Ages 18 and older, biological parent of a CF patient who is also enrolled in the study Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)
Group III: Cystic Fibrosis (IS, HS)Experimental Treatment4 Interventions
CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day. Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)
Group IV: Cystic Fibrosis (HS, IS)Experimental Treatment4 Interventions
CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day, Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hypertonic Saline
2006
Completed Phase 4
~670
Isotonic Saline
2018
Completed Phase 4
~1010
Gelatin
FDA approved
Indium
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,836 Previous Clinical Trials
47,850,992 Total Patients Enrolled
37 Trials studying Cystic Fibrosis
12,646 Patients Enrolled for Cystic Fibrosis
Tim CorcoranLead Sponsor
1 Previous Clinical Trials
24 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
24 Patients Enrolled for Cystic Fibrosis
Tim Corcoran, Ph.D.Principal InvestigatorUniversity of Pittsburgh
3 Previous Clinical Trials
52 Total Patients Enrolled
3 Trials studying Cystic Fibrosis
52 Patients Enrolled for Cystic Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Multilevel Models of Therapeutic Response in the Lungs
Tim Corcoran 2017. "Multilevel Models of Therapeutic Response in the Lungs". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02947126.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top